 Immunogenic conjugates comprising leukotoxin peptide fragments |
| OF THE INVENTION Substances having molecular weights less than 1000 daltons are not ordinarily ... |
|
| Interleukin-2-leukotoxin gene fusions and uses thereof |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| GnRH-leukotoxin chimeras |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| GNRH-leukotoxin chimeras |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Polynucleotides encoding LKT 111 |
| The practice of the present invention will employ, unless otherwise indicated, conventional ... |
|
| Methods and compositions for the treatment of defects in lipoprotein metabolism |
| In one aspect, the invention provides a recombinant viral vector comprising the DNA of, or ... |
|
| Antisera against a PEB1 antigen from Campylobacter jejuni |
| It is an object of the present invention to provide highly specific and highly sensitive diagnostic ... |
|
| Gene encoding invasion protein of campylobacter species |
| OF PREFERRED EMBODIMENTS The following standard abbreviations for the amino acid residues are used ... |
|
| Preservatives for vaccines |
| New combinations of preservatives that pass antimicrobial testing requirements for United States P... |
|
|
Recombinant parainfluenza virus expression system and vaccines
| Details |
Inventors: Haller, Aurelia; Coelingh, Kathleen L.;
Assignee: MedImmune Vaccines, Inc. (Mountain View, CA)
Primary Examiner: Salimi; Ali R.
Assistant Examiner:
Attorney, Agent or Firm: Jones Day
The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens. |
|
DETAILED DESCRIPTION What is claimed is: 1.
An immunogenic formulation comprising a chimeric parainfluenza virus comprising (i) nucleotide sequences of Kansas-strain bovine parainfluenza virus type 3 genome comprising nucleotides 1-5041 and nucleotides 8529-15,456 of the genome of Kansas strain bovine parainfluenza virus type 3; and (ii) F and HN gene sequences of human parainfluenza virus type 3.
2.
An immunogenic formulation comprising a chimeric parainfluenza virus comprising: (i) nucleotide sequences of Kansas-strain bovine parainfluenza virus type 3 genome; and (ii) the F and HN gene sequences of human parainfluenza virus type 3, wherein (i) PCR amplification of nucleotide 5,255 to 6,255 of the chimeric parainfluenza virus results in a DNA fragment that is recognized by restriction endonucleases Sac I and Bgl II; and (ii) PCR amplification of nucleotide 9,075 to 10,469 of the chimeric parainfluenza virus results in a DNA fragment that is recognized by restriction endonucleases Pvu II and Bam HI.
3.
An immunogenic formulation comprising a chimeric parainfluenza virus comprising (i) nucleotide sequences of Kansas-strain bovine parainfluenza virus type 3 genome comprising nucleotides 1-5041 and nucleotides 8529-15,456 of the genome of Kansas strain bovine parainfluenza virus type 3; and (ii) one or more sequences derived from RSV, Ply, New Castle Disease virus, Sendai virus, Infectious Laryngotracheitis virus or influenza.
4.
An immunogenic formulation comprising a chimeric parainfluenza virus comprising: (i) nucleotide sequences of Kansas-strain bovine parainfluenza virus type 3 genome comprising nucleotides 1-5041 of the genome of Kansas-strain bovine parainfluenza virus type 3; and (ii) one or more sequences derived from RSV, PIV, New Castle Disease virus, Sendai virus, infectious Laryngotracheitis virus or influenza.
5.
An immunogenic formulation comprising a chimeric parainfluenza virus comprising: (i) nucleotide sequences of Kansas-strain bovine parainfluenza virus type 3 genome; and (ii) one or more sequences derived from RSV, PIV, New Castle Disease virus, Sendai virus, Infectious Laryngotracheitis virus or influenza, and wherein said sequences have been added at a nucleotide position of Kansas-strain bovine parainfluenza virus type 3 selected from the group consisting of nucleotide position 5041, the HN gene, and nucleotide position 8529
|
| Related patents |
|
|
Recombinant influenza A viruses
OF THE INVENTION In one embodiment, the invention relates to genetically engineered NS gene constructs of an influenza A virus comprising sequence modifications, i.e. ...
|
|
|
Recombinant vector containing a sequence of a lipoprotein gene for the expression of nucleotide sequences
We claim: 1. A recombinant vector for the cloning, expression, and exposure at the surface of the external membrane of Gram-negative bacteria of a heterologous ...
|
|
|
Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
Surprisingly, it was found by the inventors that a hybrid protein, wherein OprI is linked with its N-terminal end to a C-terminal portion of OprF is significantly more ...
|
|
|
LktA deletion mutant of P. haemolytica
It is an object of the present invention to provide a P. haemolytica bacterium useful as a vaccine strain. It is another object of the present invention to provide a ...
|
|
|
Malaria vaccine
OF THE INVENTION It has been established that a mixture of the following novel peptide compounds represents a preferred embodiment of the present invention, namely, Tyr-...
|
|
|
Protein copolymer malaria vaccine
OF THE INVENTION It has been established that a mixture of the following novel peptide compounds represents a preferred embodiment of the present invention, namely, F...
|
|
|
Vaccine against the sporozoite stage of malaria
OF THE INVENTION The P.vivax CS gene is set forth below (together with the amino acid sequence for which its codes) ##STR1## The DNA fragment chosen for insertion in ...
|
|
|
Malaria antigen
We claim: 1. A substantially pure polypeptide comprising the amino acid sequence of a glutamate-rich polypeptide (GLURP) derived from a Plasmodium falciparum antigen ("...
|
|
|
Oligopeptide lyophilisate, their preparation and use
OF PREFERRED EMBODIMENTS The following Examples illustrate the invention. EXAMPLE 1 Approx. 1.5 liters of water for injection purposes are prepared in a suitable glass ...
|
|
|
Antithrombin nucleotides and proteins from horn fly
Isolated proteins with antithrombin activity and nucleotide sequences encoding the proteins are provided. The protein named thrombostasin is isolated from the salivary ...
|
|
|
Drugs 
